Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales0.0%
基準 2,026Target2,026million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous planForecast for the fiscal year ending March 2026: 156 → Actual results for the fiscal year ending March 2026: 1740.0%Calculated from the two disclosed figures
Key initiatives
01Project creation and identification of business assets
02Licensing, clinical trials, and business development
03Updating the business plan
Size of the Target Marketfigures 1,600, 1,379, 814, 675, 676, 122, 50, 44, 20 / growth_rate Not disclosed / source Not disclosed
Risks identified by the company
Risks related to financing
Risks related to creating investment projects and gathering information
Risks related to developing new businesses
Risks related to the growth of the investment business and business assets
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Plan period | 30 March 2026 to 31 December 2030 |
| Progress against the plan | Annual update |
| Sales Target | Forecast for the fiscal year ending March 2026: 156 → Actual results for the fiscal year ending March 2026: 174 |
| Key initiatives | Project creation and identification of business assets, Licensing, clinical trials, and business development, Updating the business plan |
| Results under the previous plan | Forecast for the fiscal year ending March 2026: 156 → Actual results for the fiscal year ending March 2026: 174 |
| Size of the Target Market | figures 1,600, 1,379, 814, 675, 676, 122, 50, 44, 20 / growth_rate Not disclosed / source Not disclosed |
| Risks identified | Risks related to financing, Risks related to creating investment projects and gathering information, Risks related to developing new businesses, Risks related to the growth of the investment business and business assets |
| Publication date | 24 June 2026 |
Items this document does not state (16)
Operating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide ongoing disclosure of the progress of investment projects, partnerships, and investment execution, and to update the matters related to the business plan and growth potential in June.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.